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Wedemonstrateanintegratedapproachtothestudyofatranscriptionalregulatorycascadeinvolved
in the progression of breast cancer and we identify a protein associated with disease progression.
Using chromatin immunoprecipitation and genome tiling arrays, whole genome mapping of
transcription factor-binding sites was combined with gene expression proﬁling to identify genes
involved in the proliferative response to estrogen (E2). Using RNA interference, selected ERa and
c-MYC gene targets were knocked down to identify mediators of E2-stimulated cell proliferation.
Tissue microarray screening revealed that high expression of an epigenetic factor, the E2-inducible
histone variant H2A.Z, is signiﬁcantly associated with lymph node metastasis and decreased breast
cancer survival. Detection of H2A.Z levels independently increased the prognostic power of
biomarkers currentlyinclinical use. This integrated approach has accelerated theidentiﬁcation of a
molecule linked to breast cancer progression, has implications for diagnostic and therapeutic
interventions, and can be applied to a wide range of cancers.
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Introduction
Cancer is caused by the accumulation of genetic mutations
combined with changes inthe epigeneticstate of affectedcells.
These changes result in the initiation and progression of
tumors, which can be described, in part, by the gene
expression proﬁles of the cancer cells in question, a unique
gene expression ‘signature,’ reﬂecting the activation or
suppression of biological pathways important in generating
the cancer phenotype (Perou et al, 1999; Sorlie et al, 2001; van
de Vijver et al, 2002; Sotiriou et al, 2003). Importantly, gene
expression proﬁling of tumors produces gene lists that do not
necessarily contribute to a measured clinical distinction, such
as the presence or absence of distant metastases. In fact, the
lack of overlap in gene lists from different studies is an
indication that, while capable of predicting patient survival,
the lists are only weakly informative with regard to mechan-
isms of oncogenesis. Many genes with statistical signiﬁcance
in a gene expression signature will not serve as viable
candidates for the development of prognostic assays or
anticancer treatments (Ein-Dor et al, 2005; Fan et al, 2006).
Use of genomic screening techniques to explore cancer cell
physiology must thereforebe followed by hypothesistesting to
validate the genes that are important for accurate prognosis
and to determine which are involved in the initiation and/or
progression of disease.
Estrogens (E2) are steroid hormones that play critical roles
in the initiation, development, and metastasis of breast and
uterine cancers (Yager and Davidson, 2006). The E2 response
in breast cancer cells is predominantly mediated by the
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factor. ERa regulates transcription of target genes through
direct binding to its cognate recognition sites, known as
estrogen response elements (EREs), or by modulating the
activityofotherDNA-boundtranscriptionfactorsatalternative
DNA sequences (Bjornstrom and Sjoberg, 2005). The proto-
oncogene c-myc is upregulated by ERa in response to E2
(Dubik and Shiu, 1992) and encodes a transcription factor,
c-MYC (henceforth MYC), which regulates a cascade of gene
targets whose products mediate cellular transformation
(Ponzielli et al, 2005). Synergy between MYC and ERa at a
subset of E2-responsive promoters has been reported, suggest-
ing a cooperative role between ERa and MYC in breast cancer
progression (Cheng et al, 2006).
Endocrine therapy, often effective for ERa-positive breast
tumors, impairs the hormone–receptor complex or inhibits E2
production. Unfortunately, a signiﬁcant fraction (B20–50%)
of ERa-positive breast tumors fails to respond (EBCTC, 1998),
or eventually develops resistance, to antiestrogen treatments
(Schiff et al, 2005). The lack of integrated and comprehensive
approaches to study pathwaysregulated byE2has delayed our
understanding of the progression to hormone resistance in
cancer.
Using an E2-dependent breast cancer cell model, MCF7
cells, we employed an integrated genomic approach that
combined E2-stimulated gene expression proﬁling and gen-
ome-wide transcription factor-binding site detection for two
essential transducersof theE2response,ERa andMYC.Recent
reports have similarly identiﬁed ERa-binding sites and E2-
activated gene expression in this cell model (Frasoret al, 2003;
Carroll et al, 2005, 2006; Laganiere et al, 2005). However,
integration of genomic screening data must be followed by
functional and clinical studies to develop useful tools for
diagnosing and treating cancer. Therefore, validation of direct
transcription factor-regulated gene targets, using gene-speciﬁc
knockdown in cell proliferation assays, was followed by
clinical correlation using primary cancer specimens with
associated data regarding patient outcomes. We demonstrate
that hormone-stimulated MYC enhances production of an
epigenetic factor, histone variant H2A.Z, the expression of
which correlates with increased probability of metastasis and
decreased patient survival. This integrated systems approach
is potentially applicable to the study of other oncogenic
pathways.
Results
Genome-wide identiﬁcation of ERa- and
MYC-binding sites in MCF7 cells
Recent studies have performed location analysis for ERa in
MCF7 cells although MYC-binding sites have been identiﬁed
only in selected cell types (such as lymphoma or leukemic cell
lines), and not using whole genome arrays (Fernandez et al,
2003; Mao et al, 2003; Cawley et al, 2004). To validate
previously reported data, and to generate MCF7-speciﬁc MYC-
binding proﬁles, tiling microarrays spanning the entire
nonrepetitive human genome were used to perform an
unbiased search for direct targets of ERa and MYC. To
recapitulate the phenotype of E2-dependent tumors, MCF7
cells were stimulated to proliferate with E2 before chromatin
immunoprecipitation (ChIP).
We identiﬁed a total of 1615 ERa-bound regions (Po1e 5)
throughout the human genome (Supplementary Table 1). The
distribution of ERa-binding regions ranged from proximal
(o1kb)tothenearesttranscriptionstartsite(TSS)ofageneto
over 500kb from the closest TSS (Figure 1A). Similarly, we
detected 311 MYC-bound regions across the human genome in
MCF7 cells (Supplementary Table 2). The distribution of MYC-
bound loci in relation to annotated TSSs is depicted in
Figure 1B. A total of 62.4% of ERa-bound regions detected in
ourstudy wereconﬁrmed in an independentlyderived dataset
using similar methods (Carroll et al, 2006) (common sites are
indicated in Supplementary Table 1).
We examined ERa- and MYC-binding regions for the
presence of predicted transcription factor-binding motifs and
detected statistically signiﬁcant enrichment of canonical EREs
(AGGTCAnnnTGACCT) in ERa-bound regions and E-boxes
(CACGTG) in MYC-bound regions (Supplementary Figures 1–
3). Although we observed strong enrichment of EREs within
ERa-bound regions of the genome, a signiﬁcant proportion of
ERa-bound regions may not contain a recognizable canonical
ERE (Supplementary Figure 3).
It is known that ERa may exert effects at non-ERE-contain-
ing chromatin targets through protein–protein interactions
with DNA-bound transcription factors, including the Fos and
Jun family complexes (i.e. AP-1) (Webb et al, 1999; Cheung
et al, 2005). Consistent with this observation, AP-1 sites were
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Figure 1 Genomic distribution of ERa- and MYC-binding sites. The
distributions of 1615 ERa-( A) and 311 MYC- (B) binding sites in E2-stimulated
MCF7 cells relative to known genes. Where multiple genomic probes indicated a
transcriptionfactor-boundregion,thecenterofeachERa-orMYC-bindingregion
was designated as the bound position. Within annotated genes, binding sites
were classiﬁed as follows: within 50 untranslated regions (50 UTR), within coding
sequences(CDS),within50-mostintronortheﬁrstintron,withinotherintrons,and
within 30 untranslated regions (30 UTR). ERa or MYC binding in intergenic
regions was further classiﬁed based on the distance to the nearest annotated
gene (0–10, 10–50, and 450kb).
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mentary Figure 1). We conﬁrmed signiﬁcant enrichment of
binding sites for the forkhead transcription factor FOXA1
(Supplementary Figure 1). These data are consistent with a
recently proposed model in which a subset of ERa regulatory
regions are ﬁrst targeted for transcriptional regulation by
FOXA1(Carrolletal,2005;Laganiereetal,2005).Additionally,
we discovered signiﬁcant enrichment of binding sites for the
GATA factor, CREB1, and MSX1 (Supplementary Figure 1).
Similar computational analyses were performed for MYC-
bound regions and signiﬁcant binding site enrichment was
detected for CREB1, CTCF, AP-2g, Sp1, and ERa (Supplemen-
tary Figure 2).
We compared binding motif enrichment in ERa-bound
regions with and without predicted EREs. We found that
AP-1-, Forkhead-, GATA factor-, and CREB1-binding motifs
are signiﬁcantly enriched in ERa-bound regions with and
without EREs (at a P-value cutoff of 0.01; data not shown).
Interestingly, the MYC-binding motif (E-box) is only signiﬁ-
cantly enriched in ERa-bound regions containing EREs
(P¼1.27E 04) but not at loci without EREs (P¼5.90E 01;
data not shown). C/EBPb and MSK1 sites are enriched in
regions without EREs (P¼5.10E 03 and P¼2.10E 03, respec-
tively) but not in regions containing EREs (P¼6.97E 01 and
P¼7.59E 02, respectively; data not shown). These results
provide hypotheses regarding alternative gene regulatory
mechanisms at ERa-bound loci depending on the presence or
absence of an ERE motif at these loci. For example, ERa
localization to sites containing C/EBPb- or MSK1-binding
motifs may principallyoccur via tethering to C/EBPb or MSK1,
or to associated cofactors. By contrast, ERa and MYC may
preferentially bind target sites that contain both EREs and
E-boxes, consistent with the signiﬁcant colocalization of
ERa- and MYC-binding regions identiﬁed by ChIP-Chip
(Supplementary Figure 4). This observation is consistent with
recent claims that MYC can synergize with ERa at E2-
responsive promoters and suggests that these factors may
physically interact to stabilize the transcriptional apparatus
(Cheng et al, 2006).
To further predict combinatorial interactions between
transcription factors, pairwise transcription factor-binding
motif enrichment in ERa- or MYC-bound loci was assessed.
The results demonstrated signiﬁcant co-occurrence of EREs
and E-boxes in both ERa- and MYC-bound regions and
suggested new relationships, such as ERE plus NF-kB-binding
motifs in ERa-bound regions and E-box plus CREB1 motifs in
MYC-bound regions (Figure 2). Together, these data suggest
that some ERa- and/or MYC-bound loci represent diverse cis-
regulatory modules wherein multiple transcription factors
mayconverge with ERE-bound ERa and/or E-Box-bound MYC
to exert gene regulatory functions.
Distribution and cross-species conservation of
ERa- and MYC-binding sites
We examined the genome-wide patterns of ERa and MYC
bindingtodeterminewhetherthesefactorstendtobelocalized
similarly within or near annotated genes. Both factors are
symmetrically distributed 50 and 30 of TSSs (Figure 3A),
suggesting that the orientation (50 versus 30) of response
elements with respect to the TSS of promoters does not
determine in vivo binding and may not inﬂuence transcription
factor function. However, ERa-binding sites were relatively
uniformly distributed from 10kb downstream to 10kb up-
stream of TSSs, whereas MYC bound more proximally, with
peak binding observed within 1kb of target TSSs (Figure 3A).
These results demonstrate that MYC displays a binding
preference for core promoters or promoter-proximal regions.
We observed that a high proportion (77.7%) of ERa-bound
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Figure 2 Pairwise transcription factor-binding motif enrichment at ERa- or MYC-bound sites. Possible combinatorial interactions between transcription factors were
tested by the enrichment of co-occurrence of transcription factor-binding motifs in ERa-( A) or MYC- (B) bound regions identiﬁed by ChIP-chip. Logo representations of
the position weight matrix or the binding motif for each transcription factor are indicated in Supplementary Figures S1 and S2. Red stars indicate statistically signiﬁcant
enrichment of binding motifs for the single transcription factors (see Supplementary Figure S1 for ERa-bound regions and Supplementary Figure S2 for MYC-bound
regions). The enrichment of each pair of transcription factors is indicated by the P-value after a Bonferroni multiple testing correction (see color legend).
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(Figure 3B), whereas 23.8% reside greater than 100kb from
any annotated TSS in human genome.
We examined the evolutionary rates of regulatory regions
bound by ERa and MYC and found that these differ. ERa-
binding regions sustained relatively high sequence conserva-
tion between human and mouse or human and rat (about 75
million year divergence times) as compared to alignments of
genomic background, whereas MYC-binding regions did not
show sequence conservation above background levels
(Supplementary Figure 5). The evolutionary conservation
of ERa-bound sites supports their putative roles as functional
cis-regulatory elements.
Interestingly, in primate genomes, those regions closer to
genestartsites,inwhich manyMYC sitespredominate, appear
to undergo more rapid evolution (Keightley et al, 2005). Our
results indicate that mutation accumulation has reached
saturatinglevelsbetweenhumansandrodentsforMYC-bound
loci, whereas evolutionary comparisons are still informative
for ERa-bound regions.
Integrated analysis of expression data with
ERa- and MYC-binding regions
It is likely that only a subset of cis-regulatory elements are
transcription factor-bound and/or functional in a given cell
type under a given cellular milieu (Harbison et al, 2004).
Combining gene expression data in the presence and absence
of an activated transcription factor with data from transcrip-
tion factor localization identiﬁes the activated or repressed
genes that are likely to be direct targets (Gao et al, 2004).
Wemeasured geneexpressionchangesinMCF7cellsafter4,
12, and 24h of E2 treatment (Figure 4 and Supplementary
Table 3). Gene expression proﬁling was combined with direct
ERa-binding site localization to reveal that 5.1% of ERa-
bindingsiteswerewithin10kboftheTSSofanyE2-responsive
gene(SupplementaryTable4),consistent withtheobservation
that ERa often binds far from target TSSs (Figures 1A and 3B).
Nevertheless, these results revealed signiﬁcant enrichment of
receptor binding near regulated genes when compared to
expectations generated by a random distribution model
(Po5.4e 6). When we considered ERa-binding sites within
200kbofanyTSS,wefoundthat39%wereinthevicinityofan
E2-responsive gene (Po4.1e 12). The 61% of ERa-binding
sitesthat weregreaterthan 200kbfromanyE2-responsiveTSS
may be regulating genes from extreme distances, may be
regulating genes that are not currently annotated or may be
inactive in MCF7 cells.
A systems-level analysis of E2 targets was performed by
combining global protein–protein interaction data with our
data from ERa and MYC location analyses and our measured
E2-dependentchangesingeneexpression(Figure5)(Perietal,
2003; Stark et al, 2006). Several interesting modules involved
in cellular proliferation were identiﬁed within the E2 signaling
network. Enrichment for modules related to nucleic acid and
protein metabolism is highlighted (Figure 5). The complete set
ofpairwiseinteractionsofproteinsinvolvedintheE2signaling
cascade is presented in Supplementary Table 5. Presented in
thisway, thedatasuggestnew functionalrelationshipsbetween
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Figure3 ERa-andMYC-bindingsitedistributions proximaltoTSSs.(A)Histo-
gramsofERa-(upperpanel)andMYC-(lowerpanel)bindingsitesresidingwithin
the downstream 10kb or upstream 10kb genomic regions relative to annotated
TSSs. Where multiple genomic probes indicated a transcription factor-bound
region, the center of each ERa- or MYC-binding region was designated as the
bound position. Negative and positive values indicate transcription factor-binding
regions located 50 or 30 of neighboring TSSs, respectively. (B) The proportion of
ERa- or MYC-binding sites within a given distance (up to 10kb) from a known
TSS. Both orientations (50 and 30) relative to each TSS are considered.
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Figure 4 Time course of E2-responsive genes in MCF7 cells. Time course of
signiﬁcantly up- and downregulated genes in MCF7 cells after stimulation with
10nM17b-estradiol(E2)isshown.Overlappinggenecountsforthreetimepoints
(4, 12, and 24h) are shown for upregulated (A) and downregulated (B) genes
(all Po0.01).
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inﬂuenced by protein–protein interactions. Herewe discuss our
ﬁndings generated by this systems-level analysis, focusing on
E2 signaling cascade connections that we uncovered within the
cell cycle, within other major cellular signaling modules, and
associated with chromatin remodeling.
Multifaceted estrogen-mediated regulation of the
cell cycle
To better understand E2-mediated signaling networks, we
measured the associations of ERa and MYC gene targets with
hundreds of a priori deﬁned gene sets (such as signaling
pathways and cancer gene signatures) available in databases
including Gene Ontology (GO) (Ashburner et al, 2000), KEGG
(Kanehisa et al, 2006), BioCarta (www.Biocarta.com), and
GeneMAPP(Donigeretal,2003)(SupplementaryTable6).The
list of all transcription factor-bound sites corresponding to
E2-regulated genes is provided in Supplementary Table 4,
which indicates, for each E2-responsive gene, the distance to
the nearest transcription factor-bound locus. Our working
deﬁnition of a cis-regulatory element corresponding to a given
E2-responsive gene (criteria Po0.01 for at least one time point
performed at least in triplicate; see Supplementary informa-
tion) was limited to a transcription factor-bound locus within
MYC binding
E2 regulated only
ERα binding
MYC binding and E2 regulated
MYC binding and ERα binding
ERα binding and E2 regulated
Protein synthesis
Protein degradation
DNA synthesis
mRNA processing
A
C
B
Figure 5 A protein–protein interaction network of E2 signaling targets. (A) Overview of the protein–protein interaction network of E2 signaling targets. The nodes
represent target genes that are E2-regulated, or harbor ERa-binding sites within 50kb of their TSSs, or harbor MYC-binding sites within 20kb of their TSSs (see color
legend).Thenodesize correlates withthe degreeofnode connectivity. Theedges denoteprotein–protein interactions derivedfrom HumanProteinReferenceDatabase
(HPRD) (Peri et al, 2003) and the BioGRID database (Stark et al, 2006). The network was visualized using Cytoscape (Shannon et al, 2003). (B, C) Expanded views of
representative modules in the protein–protein interaction network of E2 signaling targets. Modules or highly connected subnetworks are identiﬁed with MCODE (Bader
and Hogue, 2003). The modules shown in panels B and C are functionally related to key cellular processes involved in nucleic acid and protein metabolism.
Enhancement of these functional modules may be necessary for rapid cellular growth and proliferation stimulated by E2 in breast cancer cells.
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widespread E2-mediated direction of biochemical pathways
relevant to cell survival and proliferation.
We found that ERa directly regulated genes in all phases of
the cell cycle and that MYC directly regulated a different but
overlapping set of factors (Supplementary Figure 6). We
detected signiﬁcant overlap with over 800 cell cycle genes
previously described in HeLa cells (164 out of 888, Po1e 16)
(Whitﬁeld et al, 2002) (Table I). Accordingly, when our E2-
responsive gene list was compared to GO categories, we found
signiﬁcant enrichment for terms directly connected to cell
cycle progression, including ‘M phase of mitotic cell cycle,’
‘nuclear division,’ and ‘DNA replication and chromosome
cycle’ (Supplementary Table 6).
Prior work has focused on E2-mediated control of the cyclin
D1–CDK4/CDK6 complex during G1 and on the activity of the
cyclin E–CDK2 complex in the G1/S transition (Doisneau-
Sixou et al, 2003; Caldon et al, 2006). Our genomic studies
conﬁrmed direct transcriptional activation of CCND1 by ERa
and conﬁrmed CDK4 as a direct target of MYC (Supplementary
Figure 6). However, wealso observed noveltargetssuch as the
signiﬁcant downregulation of CDK6 mRNA after E2 treatment
(Supplementary Table 3). Lower levels of CDK6 in breast
cancer cells compared with normal mammary epithelial cells
have been reported, and ectopic expression of CDK6 surpris-
ingly inhibits proliferation of mammary epithelial cells (Lucas
et al, 2004). We also observed upregulation of members of the
E2F transcription factor familyand of their heterodimerization
partner TFDP1 (Supplementary Figure 6), and our results
suggest direct transcriptional regulation of TFDP1 by ERa and
MYC and regulation of E2F6 by ERa.
E2 similarly regulates the transition of G2 to M. CDC2 was
signiﬁcantly upregulated by E2 and ERa binding near CDC2
was detected. E2-stimulated expression and ERa binding were
also detected for BUB1, which is involved in spindle
checkpoint function, and E2-regulated gene expression was
observed for spindle checkpoint genes BUB3, MAD2L1,
CDC20, PLK1, PLK4, KNTC2, and STK6 (Supplementary
Table 3). Mitotic checkpoint defects have been suggested to
explain conditions of chromosomal instability (Kops et al,
2005) although mutations in those checkpoint genes are
relatively uncommon in human tumors (Olesen et al, 2001).
Interestingly, elevated expression of MAD2L1 and BUB1 has
been correlated with advanced tumor status and poor clinical
outcomes in breast cancer (van ‘t Veer et al, 2002) and
neuroblastoma (Hernando et al, 2004). Levels of many mitotic
checkpoint proteins are also higher in breast cancer cell lines
than in normal mammary epithelial cells (Yuan et al, 2006).
Similarly, we found that the gene for d-tubulin (TUBD1),
a component of centrioles and the mitotic spindle, is
upregulated by E2 and the gene has nearby binding sites for
both ERa and MYC. Vinca alkaloids and taxanes, which target
a- and b-tubulins, are effective therapies limited by
widespread toxicities to normal cells. To date, no targeted
therapy has been developed for d-tubulin.
Finally, the ras-related nuclear protein (Ran) gene is
stimulated by E2 and targeted by ERa (Supplementary Table
4 and Supplementary Figure 7). RAN plays a central role in
spindle assembly, nuclear envelope reassembly after mitosis,
anddirectstheﬂowof proteinsinto andoutof thecell nucleus.
These results demonstrate that E2 affects the cell cycle at
multiple levels.
Table I E2-regulated genes periodically expressed during cell cycle progression, and ERa- and MYC-bound loci
Cell cycle phase Gene symbols
Upregulated
G1/S ACYP1, CEP57, CHAF1B, E2F1, E2F2, FANCG, FLAD1, FLJ13912, GMNN, HELLS, ITGB3BP, MCM4, MCM5, MCM6,
MGC24665, NFKBIL2, NSUN5C, PCNA, Pfs2, PMS1, POLD3, RECQL4, SFRS7, SLC25A36, SSR3, TLOC1, ZMYND19
S ASF1B, ATAD2, BRIP1, C1orf73, C8orf1, CCDC14, COL7A1, DCC1, DHFR, DNA2L, EZH2, FLJ12788, FLJ25416, FUSIP1,
HIST1H4C, HSPB8, KIAA1794, LASS6, MLF1IP, PHIP, PRIM1, PRIM2A, RAD51, RFC4, RHOBTB3, RRM2, SH3GL2,
SLC38A2, TOP2A, UBE2T
G2 BCDIN3, BRD8, BUB3, C12orf32, C1orf155, C20orf129, CBX5, CCNA2, CDC2, CDC25C, CDCA2, CDCA8, CHEK2,
DKFZp762E1312, FLJ10038, FLJ22624, H2AFX, hCAP-D3, HIPK2, KIF11, KIF22, KIF23, KIFC1, KNTC2, MELK, MND1,
NY-SAR-48, RGS3, SMC4L1, STIL, TMPO, TTF2, TUBD1, UBE2C, WDR68
G2/M ANLN, AURKA, BMP2, BUB1, C15orf23, CCNB2, CDCA1, CDCA3, CENPA, CENPE, CEP55, CIT, CKS2, CNOT10, CTCF,
DEPDC1, DLG7, ECT2, EPR1, FAM64A, GTSE1, HCFC1, HN1, NEK2, NUSAP1, PRR11, RAD51C, RNF141, SHCBP1, SPAG5,
TPX2, TRIP13, USP16, YWHAH, ZMYM1
M/G1 AMD1, ANP32E, AOC2, CBX3, CCND1, CDKN3, DKC1, GATA2, HIF1A, HSPA8, HSPC196, ILF2, MORF4L2, NUCKS1,
NUDCD2, NUP37, PBK, PLK1, RAN, SLC39A10, STAG1, TROAP
Downregulated
G1/S HIST2H2AA
S ABCC5, EGFL5, FLJ13231, KIAA1370, RRM1, SLC9A3, ZNF217
G2 CDKN2C, FLJ20699, KCTD9, LOC284219
G2/M N4BP3
M/G1 AKAP13, PLK2
ERa targets
c-MYC targets
Common targets
The table identiﬁes 164 E2-regulated genes (149 upregulated and 15 downregulated) in MCF7 cells, which were identiﬁed as periodically expressed genes during cell
cycleprogressioninHeLacells(Whitﬁeldetal,2002).Thesegenesarefurthergroupedbasedoneachcellcyclephase(G1/S,S,G2,G2/M,andM/G1).Genescontaining
ERa- or MYC-bindingsites areindicated in blue andgreen,respectively. Common targetsfor both ERa andMYC arelabeled in red.Asigniﬁcant fractionof the cellcycle
genes (49 out of 164, Po3.2e 9) identiﬁed in our study contain binding sites for ERa and/or MYC within 200kb of the TSS, supporting substantial and direct
transcriptional control of the cell cycle apparatus mediated by these transcription factors.
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signaling pathways
Some of the pleiotropic effects of ERa signaling are due to
cross-talk with signaling pathwaysincluding those responding
to growth factors and/or involving MAPK, PI3K, and PKA
(Bjornstrom and Sjoberg, 2005). We investigated the extent of
cross-talk between ERa signaling and many other known
pathways curated in BioCarta and GenMAPP. Epidermal
growth factor (EGF) signaling and insulin-like growth factor
1 (IGF-1) signaling were among the top pathways to be
signiﬁcantly enriched in our data set. Representative genes
responsive to E2 and harboring ERa- or MYC-binding sites
involved in these pathways are shown in Supplementary
Tables 4 and 6.
We identiﬁed a signiﬁcant enrichment of E2 target genes in
the pathway of the mammalian target of rapamycin (mTOR)
(Supplementary Table 6). mTOR is a conserved Ser/Thr
kinase-activated protein important in the pathogenesis of
cancer, cardiovascular disease, and metabolic disorders (Choo
andBlenis,2006). Wedetected ERabindingandsigniﬁcant E2-
stimulated expression of the gene for RHEB, a protein that
promotes TOR signaling. We detected both ERa- and MYC-
binding sites near the gene for the ribosomal protein S6 kinase
(RPS6KB1), a critical target of TOR signaling whose activity
leads to increased protein synthesis and cell proliferation.
Ampliﬁcation of the region of DNA encoding this gene and
overexpression of this kinase are seen in some breast cancers
and are associated with poor prognosis and metastasis (van
der Hage et al, 2004). These results indicate that cross-talk
between E2-stimulated ERa and growth factor signaling
pathways occurs at multiple levels including the regulated
expression of genes essential for growth factor signaling.
Estrogen-regulated expression of chromatin
factors
Epigenetic alterations play critical roles in tumorigenesis and
cancer progression (Lund and van Lohuizen, 2004; Feinberg
et al, 2006). We identiﬁed targets of E2 involved in many
aspects of epigenetic regulation (Figure 6). Members of the
Polycomb group involved in transcriptional silencing, includ-
ing EZH2 and EED, both components of the Polycomb
repressive complex 2 (PRC2), were upregulated by E2
(Figure 6). In addition, E2 activated the expression of other
genes associated with PRC2 activity, including HDAC2,
DNMT1, and HMGB1. HDAC2 has been shown to interact
with EED in vivo and DNMT1 can be recruited to target genes
by interacting with EZH2. The Drosophila homologue of
HMGB1, Dsp1, plays an essential role in recruiting Polycomb
proteins to target chromatin. Although the speciﬁc targets of
Polycomb complexes in breast epithelial cells are largely
unknown, the overexpression of components associated with
PRC2byE2isintriguingbecausehighlevelsofEZH2havebeen
associated with increased cancer cell proliferation, tumor
invasiveness, and poor prognosis in breast cancer (Kleer et al,
2003).
Histone modiﬁers including HDAC3 and HAT1 were E2
responsive (Figure 6) and HAT1 harbors an ERa-binding site.
Two methyl-DNA-binding proteins involved in gene silencing,
MeCP2 and MBD3, demonstrated E2-regulated gene expres-
sion and MeCP2 was ERa-bound. E2 regulated the histone
chaperones CHAF1B, targeted by ERa, and ASF1B. CAF-1 and
ASF1B cooperate to deposit histones into newly synthesized
DNA at replication forks. The upregulation of these histone
chaperones and DNMT1, the principal maintenance DNA
methyltransferase recruited to DNA replication foci, may be
necessary to regulate epigenetic inheritance of histone
modiﬁcations and DNA methylation patterns in proliferating
MCF7 cells in response to E2. These gene products may
provide a novel epigenetic signature of cellular proliferation,
as recently suggested for CHAF1B (Polo et al, 2004).
Variant histones have been suggested to produce an
additional layer of epigenetic gene regulation. E2 enhanced
the expression of two H2A variants, H2A.X and H2A.Z, and
MYC-binding sites were detected for both genes (Figure 6). E2
also enhanced expression of several proteins involved in
regulating and/or maintaining higher-order chromatin struc-
ture, including heterochromatin protein HP1a, the boundary
element-binding protein CTCF, and the high-mobility group
proteins HMGB1 and HMGN1 (Figure 6), suggesting active
epigenetic reprogramming in breast cancer cells.
RNAi of ERa and MYC targets in MCF7 cells
We selected a subset of E2-inducible targets of ERa and MYC
for functional analysis and compared these to several genes
with no reported or detectable role in E2 signaling. RNAi
targets also included known oncogenes, transcription factors
and cofactors, and regulators of the cell cycle. RNAi-mediated
depletion of ERa resulted in marked reduction in MCF7
growth, demonstrating the essential role of this receptor in
the maintenance of these cells (Figure 7). RNAi-mediated
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Figure 6 Targets ofE2signaling participate inepigeneticregulation.Targetsof
E2 signaling involved inepigenetic regulationof gene expression were observed.
These chromatin factors include the components in Polycomb group (PcG)
complexes, DNA methyltransferases and methyl-DNA-binding proteins, histone
modiﬁers, histone chaperones, varianthistones, andproteinsmaintaining higher-
order chromatin structure. Gene expression changes upon E2 treatment are
color-coded (log2-transformed fold changes). Genes for which ERa or MYC
binding was detected (ChIP-chip sites) are indicated and the location of the
binding site relative to the TSS is depicted (see color legend).
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proliferation. Impaired cell proliferation was observed after
RNAi of RAN, required for DNA synthesis and spindle
assembly, Supervillin (SVIL), which serves as a nuclear
receptor coactivator and an actin-binding protein, the tran-
scription factor FOXA1 (discussed above), the chromatin
factors GATA1 and GATA3, and the variant histone H2A.Z
(Figure 7).
Reduction in cell proliferation ranged from minor but
statistically signiﬁcant effects to nearly complete loss of cell
growth. In most cases, the inhibition of cell proliferation was
observed in both E2-stimulated and vehicle-treatedMCF7 cells
and some E2-dependent growth enhancement was preserved.
These results are consistent with our observation that
E2-stimulated proliferation is mediated by genes in multiple
pathways, in series and in parallel, such that elimination
of any single gene product may not entirely ablate the
proliferative response.
Histone variant H2A.Z as a novel epigenetic
marker of breast cancer progression
GATA3 and FOXA1 expressions have been shown to correlate
with breast cancer response to therapy and overall patient
survival (Lacroix and Leclercq, 2004; Mehra et al, 2005). We
reasoned that some of the gene targets that we identiﬁed may
similarly serve as useful prognostic tools. In particular, we
were interested in focusing on chromatin remodeling factors
because of the proposed role in epigenetic dysregulation in
cancer progression (Lund and van Lohuizen, 2004; Feinberg
et al, 2006). We therefore investigated the E2-stimulated gene
for histone variant H2A.Z which was bound by MYC in our
ChIP-chip assay and which demonstrated a statistically
signiﬁcant effect on cellular proliferation in the RNAi screen
(Figure 7). Furthermore, H2A.Z has never been reported to
play a role in oncogenesis although previous studies have
implicated it in chromatin remodeling, genomic stability,
chromosome segregation, and gene transcription (Adam et al,
2001).
The H2A.Z gene promoter harbors two adjacent canonical
E-boxes (CACGTG) bound by MYC (Figure 8A). ChIP-PCR
conﬁrmed that MYC is recruited to the H2A.Z promoter after
E2 treatment (Figure 8B), leading to increased gene and
protein expression in MCF7 cells (Figure 8C). Thus, H2A.Z is
induced by E2 partly via the activation of MYC.
We next interrogated a primary breast tumor-containing
tissuearrayrepresentingover500uniquesamples(Figure8D).
The intensity of H2A.Z immunostaining in these samples was
highly correlated with the presence of metastasis to lymph
nodes (Table II) and decreased patient survival demonstrated
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Figure 7 The effect of gene knockdown on basal and E2-stimulated cell
proliferation in MCF7 cells. (A) RNAi-mediated gene knockdown was performed
for selected genes of interest, listed, including those that are E2-regulated, that
harbor ERa- and/or MYC-binding sites, or that are implicated in the cellular
response to E2. (B) The location of ChIP-identiﬁed ERa and/or MYC
transcription factor-binding sites relative to the TSS of each targeted gene (A)
(see color legend). Gray color indicates that no ERa- or MYC-binding region was
detected within 200kb to the TSS of the gene. (C) E2-regulated genes identiﬁed
by gene expression proﬁling in our study are indicated (Expression), as well as
genes curated in the Dragon Estrogen Responsive Genes Database (ERGDB)
(Tang et al, 2004). (D) Proliferation assays in MCF7 cells after knocking down
each gene from panel A using RNAi. We measured the cellular proliferation of
gene-speciﬁc RNAi cells versus control cells (treated with the control siRNA)
under both E2-depleted (i.e. vehicle-treated) and E2-stimulated conditions. BrdU
incorporation rates are normalized to the data from RNAi control cells grown in
E2-depletedconditions(errorbarsdenoteone1s.d.).RNAicontrolcellsgrownin
10nM E2-treated conditions have roughly 1.5-fold higher proliferation rates than
those in E2-depleted conditions. One-way ANOVA was applied to test the
signiﬁcance of the proliferation changes for RNAi knockdown cells versus
the RNAi control cells under hormone-stimulated or basal conditions. **Po0.01,
*Po0.05.
Genomic analysis of estrogen response in cancer
S Hua et al
8 Molecular Systems Biology 2008 & 2008 EMBO and Nature Publishing Group48
120
H2A.Z
E2 (h) 0 6 12 24 36
+1
TSS E-box
–305 H2A.Z
MYC
Input
E2 (min) 0 45
–387
E-box
1.0
0.9
0.8
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
Survival time (months)
0 5 2 0 5 1 0 0 1 0 5 0 200
H
L
M
Censored
Figure8 H2A.ZisatargetoftheE2cascadeandisassociatedwithbreastcancerprogression.(A)TheH2A.ZpromoterharborstwocanonicalE-boxes(50-CACGTG-
30), which serve as MYC response elements. (B) ChIP-PCR demonstrates that MYC is recruited to the H2A.Z promoter in MCF7 cells after E2 (10nM) exposure.
(C) Western blot demonstrates the induction of H2A.Z protein level in MCF7 cells in response to E2 (10nM). (D) Immunohistochemical staining of tissue arrays for
H2A.Z protein. Tissue microarrays were stained with an antibody speciﬁc for H2A.Z (brown and arrows) and counterstained with hematoxylin (blue and arrowheads).
Three representative tumor samples with differing H2A.Z protein levels are shown (from upper to lower panel: low, moderate, and high staining). For each tissue
shown on the left ( 60 magniﬁcation), the inset is highlighted in the corresponding right panel ( 180 magniﬁcation). (E) Kaplan–Meier curves of overall patient
survival for 517 breast cancer patients with corresponding variations in H2A.Z tumor expression (low (L): 98 patients; moderate (M): 326 patients; and high (H):
93 patients). The P-value is calculated based on the log-rank test.
Table II High H2A.Z expression is an independent marker associated with decreased patient survival
Variable Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Nodal status o0.0001 o0.0001
Positive 2.31 (1.82–2.96) 2.03 (1.52–2.73)
Nuclear grade 0.0018 0.38
High (3/3) 1.52 (1.17–1.96) 1.14 (0.84–1.53)
H2A.Z expression 0.0004 0.027
High 1.73 (1.29–2.31) 1.44 (1.04–1.97)
E2 receptor status 0.060 0.63
Negative (0/3) 1.25 (1.00–1.59) 1.07 (0.81–1.42)
Progesterone receptor status 0.042 0.20
Negative (0/3) 1.28 (1.01–1.62) 1.20 (0.91–1.59)
HER2/neu status 0.19 0.052
Positive (2–3/3) 1.23 (0.90–1.65) 1.45 (1.00–2.06)
Tumor size (per cm) 1.15 (1.10–1.20) o0.0001 1.10 (1.04–1.16) 0.0010
CI, conﬁdence interval.
UnivariateandmultivariateanalysesofoverallbreastcancerpatientsurvivalwereperformedbasedonCoxproportional-hazardsregressionmodels.Hazardratioswith
95% CIs are indicated. Statistically signiﬁcant observations (Po0.05) are in boldface.
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results were observed when H2A.Z protein levels were
analyzed using a newly established tissue microarray staining
and scoring technology (Camp et al, 2002), as well as when
measuring H2A.Z mRNA levels using an independent cohort
of 295 tumor samples from a published transcriptome study
(van de Vijver et al, 2002) (Supplementary Figure 7).
The predictive value of H2A.Z protein expression on breast
cancer survival was assessed by univariate and multivariate
analyses based on Cox proportional-hazards regression
models (Table II). Univariate analysis conﬁrmed that high
expression of H2A.Z is signiﬁcantly associated with shortened
overall survival. The multivariate analysis showed that H2A.Z
expression is retained as an independent predictor of survival
and provides signiﬁcant prognostic information independent
of standard clinicopathologic measures. Because H2A.Z
expression remained signiﬁcant in a multivariate analysis
with factors including lymph node status, grade, and tumor
size, it added prognostic information beyond what these
factors alone provide.
Discussion
This integrated analysis of genome-wide transcription factor-
binding sites combined with comprehensive gene expression
proﬁling data sets enabled the identiﬁcation of direct gene
targetsforERaandMYC,bothmediatorsoftheE2proliferative
response. Overlay of these data with protein–protein interac-
tion maps and GO annotation revealed enrichment for several
biological modules. RNAi, when combined with cell prolifera-
tion assays, enabled conﬁrmation of functional contributors to
the E2-stimulated proliferative response. Complete genome
coverage enabled powerful bioinformatic analyses to detect
enriched sequence motifs within the identiﬁed regulatory
regions.
A signiﬁcant fraction of ERa-binding sites (nearly 80%)
were located greater than 10kb from any annotated TSS. Nye
et al (2002) demonstrated that ERa displays the ability to alter
large-scale chromatin structure when tethered or directly
bound to DNA (Nye et al, 2002). Together, these observations
imply long-range interactions between ERa regulatory regions
and target promoters, closely tied to higher-order chromatin
conformational changes (such as chromatin decondensation,
compaction, and territory formation). Some chromatin
changes are initiated by unliganded ERa (Apo-ERa) and may
maintain targets in a state that is poised for rapid gene
activation once stimulated by E2 (Metivier et al, 2004).
Large-scale processive/propagated changes in chromatin
structure (i.e. chromatin opening) have yet to be shown to
independently activate gene transcription in mammalian cells
but may potentiate additional gene activation events. Alter-
natively, distant binding sites may physically participate in
coregulatorrecruitmenttotargetpromotersviaDNAlinkingor
looping (Bulger and Groudine, 1999). A recent study showed
that half of conserved noncoding elements with great
regulatory potential were located more than 250kb away from
their associated genes (Vavouri et al, 2006). Long-range intra-
chromosomal, or recently characterized interchromosomal,
interactions maycontribute to regulatory complexity in higher
eukaryotes (Spilianakis et al, 2005; Ling et al, 2006).
Importantly, our analysis shows that fewer than half of
chromatin fragments associated with ERa contain near-
consensus ERE sequences. This result suggests that the
majority of chromatin regions targeted by ERa consist of
cis-regulatory modules wherein ERa is tethered to DNA
by interacting transcription factors or binds to highly
variant EREs.
Our data extend the current understanding of E2-mediated
regulation ofthecell cycle bysigniﬁcantlyexpandingthelistof
direct and indirect targets of ERa and MYC whose products
participate in diverse cellular pathways relevant to cancer cell
proliferation and viability. We intend to pursue our character-
ization of newly deﬁned gene targets of ERa and MYC with a
view to better characterizing the essential participants that
support oncogenesis, metastasis, and resistance to hormonal
therapy and chemotherapy. Our approach will continue to
include widespread functional analysis of candidate genes
using RNAi in proliferation assays; promising candidates can
thenbetestedusingprimarytumorsamplesfromtissuearrays.
Blocking the ERa pathway with antiestrogens provides an
important therapy in the management of receptor-positive
cancers, including B70% of breast cancers. Unfortunately,
this therapy is hindered by the subsequent development of
tumors resistant to antiestrogen treatment, a process that
can involve an E2-autonomous MYC (Rodrik et al, 2005).
However, resistance to antiestrogens also appears to be
mediated via bidirectional cross-talk between liganded or
apo-ERa and participants in the intracellular signaling
cascades engendered by growth factor receptors such as Her-2/
neu (ERBB2) (Schiff et al, 2005). Previous studies suggest
that the full mitogenic effects of polypeptide growth factors
such as EGF, IGF-I, and TGF-a in some cells require the
presence of a functional ERa (Curtis et al, 1996). Our data
indicate an additional level of cross-talk between E2 and
growth factors: many genes for participants in growth factor
signal transduction cascades are directly regulated by ERa
and/or MYC (Supplementary Table 6).
Because of the heterogeneity of tumor gene expression
signatures (Pan et al, 2005), and the poor correlation between
tumor gene signatures and genes mechanistically essential for
tumorigenesis, it has been difﬁcult to identify gene targets
that might enable the development of new cancer therapies
(Ein-Dor et al, 2005). Our integrated analysis of ERa and MYC
permitted rapid identiﬁcation of the mechanism of H2A.Z
induction by E2 in breast cancer cells and motivated
quantitation of this chromatin protein in primary breast
tumors. H2A.Z is a novel target of E2 action in breast cancer
cells, correlates with aggressiveness of the tumor, and may
serve as an important prognostic marker when assessing
primary tumors as well as a target for directed therapy. The
observed association betweenH2A.Z overexpression and poor
clinical outcomes implies that a variant histone replacement
pattern is a marker for, and possibly a cause of, increased
tumor aggressiveness.
Although MYC stimulates H2A.Z expression (Figure 8A–C),
H2A.Z protein has been reported to downregulate the
expression of c-myc in a promyelocytic cell line in a process
that provokes RNA polymerase II stalling at the gene promoter
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of H2A.Z with the core histone H2A. These data suggest the
potential for feedback regulatory loops between MYC and
H2A.Z gene expression. H2A.Z was recentlyshown to mediate
localization of genes to the nuclear periphery in a process that
may confer memory of previous transcriptional states to
promote rapid gene reactivation (Brickneret al, 2007). In addi-
tion, H2A.Z participates in the CTCF-containing boundary/
insulatorcomplex (Yusufzai et al, 2004). It is thus intriguing to
note that, in MCF7 cells, E2-stimulated expression and
ERa binding was detected for the CTCF gene, which, in turn,
regulates MYC gene expression and can inhibit apoptosis
(Docquier et al, 2005). Complex patterns of feedback
regulation, or dysregulation, between these players may help
dictate the proliferative phenotype in some breast cancer cells.
The factors that determine H2A.Z placement throughout the
mammalian genome are not well characterized.
Finally, GATA3 and ERa were recently shown to participate
directly in reciprocal positive regulatory loops (Eeckhoute
et al, 2007), and clinical studies indicate that GATA3 is a good
prognostic marker and predicts hormone responsiveness in
breast tumors (Mehra et al, 2005). The signiﬁcant enrichment
of binding motifs of GATA family transcription factors in ERa-
bound regions supports a hypothesis of transcription factor
synergy in breast cancer cells. We found that a signiﬁcant
number of GATA3-induced genes in human 293Tcells (Usary
et al, 2004; Oh et al, 2006) are also direct targets of ERa
identiﬁed by ChIP (85 out of 295, Po1e 16; data not shown).
When knocking down GATA3 expression by RNAi, we
observed severe proliferation defects in MCF7 cells (Figure 7),
consistent with a role for GATA3 in regulating ERa production
and function.
GATA3 plays an important role in establishing long-range
chromatin changes during Th2 cell differentiation (Spilianakis
andFlavell,2004).TheseobservationssuggestthatGATA3may
modulate ERa regulatory activity on a subset of genes essential
for cellular proliferation, possibly via modifying regional
chromatin. The power to detect cis-regulatory modules acting
at important genomic loci should pave the way to developing
new diagnostic and therapeutic strategies in oncology.
Materials and methods
Cell culture
MCF7 cells (ATCC) were grown as described (Carroll et al, 2005) and
cells were changed to E2-depleted, phenol-free media for 72h before
E2 treatments.
Reverse transfection with siRNAs
Reverse transfection with Dharmafect (Dharmacon) was carried
out by using 50nM of control or gene-speciﬁc siRNA in each well of
a 96-well plate and 5000 cells/well according to the manufacturer’s
protocol. Cells were treated with 1nM E2 or vehicle for 24h. Gene-
speciﬁc siRNA oligonucleotide sequences are listed in Supplementary
information.
Cell proliferation and BrdU incorporation assays
Cellular proliferation was measured using 5-bromo-20-deoxyuridine
(BrdU) incorporation into DNA of replicating cells. The BrdU assay
was performed using an enzyme-linked immunosorbent assay-based
chemiluminescent kit (Roche) according to the manufacturer’s
protocol.
Western blotting
Celllysatesin1%SDSlysisbufferwerequantiﬁedusingtheMicroBCA
Protein Assay Kit (Pierce), and 40mg of total protein per well was
separated by SDS–PAGE, transferred to PVDF membranes, and probed
with antibodies against H2A.Z (Upstate, no. 07-594 at 1:5000) or
loading control b-actin (Abcam, ab6276 at 1:10000). Secondary
antibodies (conjugated with horseradish peroxidase) were incubated
at adilutionof1:3000,andblotsweredevelopedusingAmersham ECL
Plust Western Blotting Detection Reagents according to the manu-
facturer’s protocol (GE Healthcare).
Gene expression proﬁling
Gene expression proﬁling and analysis were performed as described
previously (Rifkin et al, 2003). Brieﬂy, total RNA was isolated using
Trizol (Invitrogen) according to the manufacturer’s instructions.
Poly-A mRNAwas puriﬁed from total RNA and cDNAs were prepared
from 2mg poly-A RNA and labeled using the Powerscript ﬂuorescent
labeling kit (BD Biosciences) and monofunctional Cy3 and Cy5 dyes
(Amersham/Pharmacia) as per the manufacturer’s protocol. The
OHU21K human oligonucleotide array (Yale’s Keck Facility) was
hybridized at 641C in a hybridization buffer consisting of 2.83 SSC,
0.5mg/ml polyadenylic acid (Sigma), and 0.18% SDS. The arrays were
washed and scanned in an Axon 4000 array scanner as described
previously (Rifkin et al, 2003). Each hormone treatment was
performed at least three times and hybridizations included dye swaps.
DataanalysisusingMAANOVAandWinABAGELv.3.6aredescribedin
Supplementary information.
ChIP-chip experiments
MCF7 cells were E2-deprived for 3 days and then were treated with
10nM E2 (45min and 2h for mapping ERa- and MYC-binding sites,
respectively) at 80% conﬂuence. An E2 exposure for 45min has been
demonstrated to produce maximal ERa binding to chromatin (Shang
et al, 2000; Carroll et al, 2005). B5 10
6 cells per ChIP were
crosslinked with 1% formaldehyde for 10min at 371C and then
quenched with 125mM glycine. The cells were washed with cold PBS
and scraped into PBS with protease inhibitors (Roche). Cell pellets
were resuspended in ChIP lysis buffer (1% SDS, 10mM EDTA, 50mM
Tris–HCl (pH 8.1)) and sonicated (Fisher Sonic Dysmembrinator). The
sheared chromatin was submitted to a clariﬁcation spin and the
supernatant then used for ChIP or reserved as ‘input’. Antibodies used
were anti-ERa (Ab-1, Ab-3, and AB-10; Lab Vision), anti-ERa (MC-20),
anti-MYC (N-262), normal rabbit IgG (sc-2027) (all Santa Cruz), and
mouse IgG (Upstate, no. 12-371). For ChIP-PCR assays, forward and
reverse primer sequences in the H2A.Z promoter were 50-GCTACA
TACCGAGGAGACTTCA-30 and 50-AGGGAAGAAACAGAGCGAGCTA-30.
For ChIP-chip, both ChIP DNA and input DNA were subjected to the
linker-mediated ampliﬁcation and ChIP and input DNA samples were
furtherfragmentedwithDNaseIandthenend-labeledwithbiotin.The
resulting samples were hybridized to Affymetrix GeneChip
s Human
Tiling 2.0R Arrays as per the Affymetrix
s ChIP protocol. Independent
biological triplicates were performed for each transcription factor and
for the control (input). Data analysis is described in Supplementary
information.
Tissue array immunohistochemistry
Detailed description of the multiple tumor tissue array design,
immunohistochemistry scoring, and data analysis is provided in
Supplementaryinformation.Brieﬂy,forimmunohistochemistry,tissue
array slides were deparafﬁnized by rinsing with xylene, followed by
two washes with 100% EtOH and two washes with water. The slides
were then boiledin sodiumcitratebuffer (pH 6.0)forantigenretrieval.
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with 2.5% hydrogen peroxide in methanol for 30min at room
temperature. The slides were then washed with Tris-buffered saline
(TBS),incubatedin0.3%BSA/1 TBSfor30minatroomtemperature
to reduce nonspeciﬁc background, and then stained with antibody
against H2A.Z (Upstate, no. 07-594) at 1:5000 dilution in BSA/TBS at
41C overnight. The slides were rinsed three times in 1 TBS/0.05%
Tween 20. Bound antibody was detected by applying anti-rabbit
horseradish peroxidase-labeled polymer secondary antibody from the
DAKO EnVision kit. The slides were washed with 1 TBS/0.05%
Tween 20 and incubated for 10min in 3,30-diaminobenzidine
in buffered substrate (Dako). Counterstaining was performed
with hematoxylin and slides were mounted with Immunomount
(Shandon).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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